Table 1.
Clinical characteristics of patients with DM.
| Characteristics | Patients with DM % (n/N) or mean ± SD/median (IQR) |
|---|---|
| Female/male ratio | 108/42 |
| Onset age (yrs, mean ± SD) | 48.87 ± 13.05 |
| Disease duration (months, median (IQR)) | 8.5 (2.4-24) |
| Treatment naïve | 32% (48/150) |
| Clinical features | |
| Muscle weakness | 66.7% (100/150) |
| Myalgia | 39.3% (59/150) |
| Heliotrope sign | 50.7% (76/150) |
| Gottron papules | 58.7% (88/150) |
| Mechanic's hands | 33.3% (50/150) |
| Raynaud phenomenon | 7.3% (11/150) |
| Skin ulcer | 19.3% (29/150) |
| Arthritis/arthralgia | 32% (48/150) |
| Dysphagia | 27.3% (41/150) |
| ILD | 68% (102/150) |
| RP-ILD | 19.3% (29/150) |
| Malignancy | 15.3% (23/150) |
| Laboratory examinations | |
| ANA-positive | 32.9% (47/143) |
| Anti-ARS | 20.7% (31/150) |
| Anti-MDA-5 | 26% (39/150) |
| Anti-TIF1γ | 13.3% (20/150) |
| Anti-NXP2 | 5.3% (8/150) |
| Anti-Mi-2 | 5.3% (8/150) |
| Anti-SAE | 2% (3/150) |
| MSA negative | 27.3% (41/150) |
| CK levels (26-200 IU/l) | 80 (37-253) |
| LDH levels (100-250 IU/l)a | 237 (183-342.5) |
| CRP levels (<0.8 mg/dl)b | 0.518 (0.187-1.158) |
| ESR levels (<20 mm/H)c | 15 (7-38.25) |
| Ferritin levels (11-306.8 ng/ml)d | 208.8 (87.65-604.9) |
| IgG (694-1620 mg/dl)e | 1210 (1003-1480) |
| CD3+ T cell percentage (50.7-86%)f | 70.7 (64.93-80.13) |
| CD4+ T cell percentage (23.3-50.2%)f | 46.45 (37.15-52.55) |
| CD8+ T cell percentage (12.5-36.9%)f | 23.85 (16.58-31.33) |
| CD19+CD5+ B cell percentage (0-0.96%)g | 3.05 (0.955-7.818) |
| CD19+CD5- B cell percentage (1.45-9.49%)g | 11.13 (6.088-16.8) |
| Pulmonary function tests | |
| % FVC (%)h | 88.53 ± 25.06 |
| % FEV1 (%)h | 86.48 ± 23.19 |
| % DLCO (%)i | 63.53 ± 18.25 |
DM: dermatomyositis; ILD: interstitial lung disease; ANA: anti-nuclear autoantibodies; ARS: aminoacyl-tRNA synthetases; MDA-5: melanoma differentiation-associated gene-5; TIF1γ: transcription intermediary factor 1γ; NXP-2: nuclear matrix protein-2; Mi-2: nucleosome remodelling deacetylase complex; SAE: small ubiquitin-like modifier-1 activating enzyme; CK: creatine kinase; LDH: lactic dehydrogenase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IgG: immunoglobulin; %FVC: percent predicted forced vital capacity; %FEV1: percent predicted forced expiratory volume in one second; %DLCO: percent predicted carbon monoxide diffusion capacity. a,b,c,d,e,f,g,h,iData were available for 149, 140, 142, 85, 144, 134, 118, 94, and 89 patients, respectively.